Completed OBSERVATIONAL NCT03146013

Dual Algorithm Post Market Clinical Study

Evaluation of the MP Diagnostics HTLV Blot 2.4

Sponsor: MP Biomedicals Asia Pacific Pte. Ltd.

Conditions HTLV I Associated Myelopathies HTLV I Associated T Cell Leukemia Lymphoma HTLV-I Infections HTLV-II Infections Human T-lymphotropic Virus 1 Human T-lymphotropic Virus 2

Interventions MP Diagnostics HTLV Blot 2.4

Updated 7 times since 2017 Last updated: Jun 9, 2017 Started: Mar 1, 2017 Primary completion: May 31, 2017 Completion: May 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates HTLV I Associated Myelopathies and HTLV I Associated T Cell Leukemia Lymphoma and is currently completed. MP Biomedicals Asia Pacific Pte. Ltd. leads this study, which shows 7 recorded versions since 2017 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Feb 2020 — Jan 2021 [monthly]

Completed
Jun 2018 — Feb 2020 [monthly]

Completed

▶ Show 2 earlier versions

Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
Jul 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Mar 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

MP Biomedicals Asia Pacific Pte. Ltd.
MP Biomedicals, LLC

Data source: MP Biomedicals, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Charlotte, United States